Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A Primer on the Management of Scleroderma Emergencies

Jason Liebowitz, MD, FACR  |  Issue: August 2020  |  July 14, 2020

Editor’s note: The 2020 ACR State-of-the-Art Clinical Symposium, which was originally scheduled to be held in New Orleans March 27–29, was moved to an online format to accommodate social distancing requirements during the COVID-19 pandemic.

ACR BEYOND LIVE—The hallmark of many rheumatologic conditions is their insidious onset and slow progression over time. Indeed, rheumatology is quite different from critical care medicine, in which patients are often acutely ill and require immediate medical intervention. This is not to say that autoimmune disease is without its share of medical emergencies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

During the 2020 ACR State-of-the-Art Clinical Symposium, Francesco Boin, MD, professor of medicine, Division of Rheumatology, University of California, San Francisco (UCSF), and director of the UCSF Scleroderma Center, provided an overview of recognition and management of three emergent situations for patients with scleroderma: critical digital ischemia, scleroderma renal crisis and intestinal pseudo-obstruction.

Critical Digital Ischemia
Raynaud’s phenomenon is almost universally present in patients with scleroderma and normally can be managed with first-line agents, such as calcium channel blockers, phosphodiesterase inhibitors and prostaglandins (frequently used in Europe). However, rather than experiencing reversible vasospasm, some patients may have vessel occlusion over time. Characterized by endothelial activation, microthrombi formation and chronic vasculopathy—either obliterative or ischemic—this condition may cause significant complications.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The clinical signs of critical digital ischemia include a dusty color of the distal digits and persistent digital pain that cannot be relieved with typical treatments. Small vessels can be affected, as well as medium-sized arteries, such as the ulnar artery. (Note: Given the possibility of poor collateral perfusion from the ulnar artery and risk of ischemia to the hand, patients with scleroderma should avoid having radial arterial lines placed whenever possible.)

When critical digital ischemia is detected, the immediate advice of treating clinicians should include rest, warmth and pain control with analgesics and digital block. Physicians should maximize vasodilative therapy with calcium channel blockers, phosphodiesterase type 5 (PDE5) inhibitors and prostacyclin infusion, if available and needed. Anti-platelet therapy with aspirin or clopidogrel can help prevent further damage. The benefits of anticoagulation and fibrinolytics remain unclear.

The most essential aspect of care is preventing advancement of ischemic territory. This may require surgical intervention.

Scleroderma Renal Crisis
Dr. Boin also discussed scleroderma renal crisis, which can present as the first manifestation of scleroderma in up to 20% of cases.1 Risk factors for scleroderma renal crisis include early diffuse cutaneous involvement of scleroderma, the presence of antibodies to RNA polymerase III, and exposure to corticosteroids or cyclosporine. Hallmark features include newly elevated blood pressure, acute renal failure, evidence of malignant hypertension, and hemolytic anemia and thrombocytopenia.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsSystemic Sclerosis Tagged with:intestinal pseudo-obstructionischemiaScleroderma Renal Crisis

Related Articles
    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Late Spring 2021’s Awards, Appointments & Announcements in Rheumatology

    April 17, 2021

    AMA Honors Mark Andrejeski with Lifetime Achievement Award In November 2020, the American Medical Association (AMA) presented Mark Andrejeski, the recently retired executive vice president of the ACR, with its Medical Executive Lifetime Achievement Award. The award honors a medical association executive who has contributed substantially to the goals and ideals of the medical profession….

    Scleroderma & the Gut: New Frontiers in Diagnosis & Tips on Management

    May 12, 2022

    McMahan et al. examined how abnormal gastrointestinal (GI) transit may contribute to GI severity and symptoms in patients with systemic sclerosis (SSc). About 90% of people with SSc have GI tract involvement, and understanding the connection between GI symptoms, their severity and abnormal GI transit may permit targeted therapeutic approaches for these patients.

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    February 17, 2018

    The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences